Anebulo Pharmaceuticals, Inc.

NasdaqCM:ANEB Stock Report

Market Cap: US$47.7m

Anebulo Pharmaceuticals Future Growth

Future criteria checks 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Anebulo Pharmaceuticals.

Key information

n/a

Earnings growth rate

n/a

EPS growth rate

Pharmaceuticals earnings growth23.6%
Revenue growth raten/a
Future return on equityn/a
Analyst coverage

Low

Last updated01 Oct 2024

Recent future growth updates

Recent updates

Here's Why We're Watching Anebulo Pharmaceuticals' (NASDAQ:ANEB) Cash Burn Situation

Jun 22
Here's Why We're Watching Anebulo Pharmaceuticals' (NASDAQ:ANEB) Cash Burn Situation

Is Anebulo Pharmaceuticals (NASDAQ:ANEB) In A Good Position To Deliver On Growth Plans?

Feb 18
Is Anebulo Pharmaceuticals (NASDAQ:ANEB) In A Good Position To Deliver On Growth Plans?

Is Anebulo Pharmaceuticals (NASDAQ:ANEB) In A Good Position To Invest In Growth?

Jul 03
Is Anebulo Pharmaceuticals (NASDAQ:ANEB) In A Good Position To Invest In Growth?

Companies Like Anebulo Pharmaceuticals (NASDAQ:ANEB) Are In A Position To Invest In Growth

Mar 07
Companies Like Anebulo Pharmaceuticals (NASDAQ:ANEB) Are In A Position To Invest In Growth

We Think Anebulo Pharmaceuticals (NASDAQ:ANEB) Can Afford To Drive Business Growth

Nov 19
We Think Anebulo Pharmaceuticals (NASDAQ:ANEB) Can Afford To Drive Business Growth

Anebulo Pharmaceuticals to launch private investment in public equity financing

Sep 26

Anebulo Pharmaceuticals GAAP EPS of -$0.10 misses by $0.03

Sep 09

Here's Why We're Not Too Worried About Anebulo Pharmaceuticals' (NASDAQ:ANEB) Cash Burn Situation

Jun 28
Here's Why We're Not Too Worried About Anebulo Pharmaceuticals' (NASDAQ:ANEB) Cash Burn Situation

Companies Like Anebulo Pharmaceuticals (NASDAQ:ANEB) Are In A Position To Invest In Growth

Mar 15
Companies Like Anebulo Pharmaceuticals (NASDAQ:ANEB) Are In A Position To Invest In Growth

Here's Why We're Not Too Worried About Anebulo Pharmaceuticals' (NASDAQ:ANEB) Cash Burn Situation

Nov 04
Here's Why We're Not Too Worried About Anebulo Pharmaceuticals' (NASDAQ:ANEB) Cash Burn Situation

Anebulo Pharmaceuticals reports FQ3 results

Jun 21

Earnings and Revenue Growth Forecasts

NasdaqCM:ANEB - Analysts future estimates and past financials data (USD Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
6/30/2025N/A-6N/AN/A1
6/30/2024N/A-8-8-8N/A
3/31/2024N/A-9-9-9N/A
12/31/2023N/A-10-10-10N/A
9/30/2023N/A-12-10-10N/A
6/30/2023N/A-12-10-10N/A
3/31/2023N/A-12-9-9N/A
12/31/2022N/A-11-8-8N/A
9/30/2022N/A-8-7-7N/A
6/30/2022N/A-7-5-5N/A
3/31/2022N/A-34-7-7N/A
12/31/2021N/A-41-6-6N/A
9/30/2021N/A-40-6-6N/A
6/30/2021N/A-38-5-5N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if ANEB's forecast earnings growth is above the savings rate (2.5%).

Earnings vs Market: Insufficient data to determine if ANEB's earnings are forecast to grow faster than the US market

High Growth Earnings: Insufficient data to determine if ANEB's earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: Insufficient data to determine if ANEB's revenue is forecast to grow faster than the US market.

High Growth Revenue: ANEB is forecast to have no revenue next year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if ANEB's Return on Equity is forecast to be high in 3 years time


Discover growth companies